Updates on the Evidence-Based Management of Osteoarthritis and Osteoarthritis Pain: Recent Guidelines and Emerging Therapies




Provided by Integrity Continuing Education, Inc.


Supported by independent educational grants from Pfizer, Inc. and Lilly.


Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 30.8 million Americans, and the prevalence of OA is increasing. The pathology of OA involves the entire joint, including cartilage degradation, bone remodeling, osteophyte formation, and synovial inflammation, which lead to pain, stiffness, swelling, and loss of normal joint function. The most commonly affected joints are the knees, hips, and hands. As a substantial contributor to disability worldwide, patients with OA experience chronic pain, loss of function, and decreased quality of life.

As a chronic disease frequently compounded by multiple comorbidities, OA management is complex and relies on a combination of pharmacological and nonpharmacological interventions. Unfortunately, the majority of patients with OA receive suboptimal therapy, and typical management is best characterized as palliative and reactive rather than coordinated, proactive, and preventative.


Francis Berenbaum, MD, PhD
Professor, Department of Rheumatology
Sorbonne University
AP-HP Saint-Antoine Hospital
Paris, France

Luana Colloca, MD, PhD, MS
Associate Professor
University of Maryland School of Nursing
Director, CTSA TL1 Pre- and Postdoctoral Training Program
School of Medicine
Baltimore, Maryland

David Hunter, MBBS, PhD, FRACP
Florance and Cope Chair of Rheumatology, Professor of Medicine
University of Sydney and Royal North Shore Hospital
Consultant Rheumatologist
Sydney, Australia

Jean Liew, MD, MS
Assistant Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts

Mohammad Ursani, MD, FACP, FACR, RhMSUS
Rheumatologist at Millennium Physicians Association
Adjunct Faculty, Internal Medicine Residency Program
University of Houston School of Medicine
Houston, Texas


Release date: June 28, 2021
Expiration date: June 28, 2022
Estimated time to complete activity: 2 hours



This educational initiative has been designed for rheumatologists, pain specialists, orthopedic surgeons, primary care physicians, radiologists, pharmacists, psychologists, physical therapists, nurse practitioners, physician assistants, and other healthcare professionals that manage patients with OA and chronic pain associated with OA.


Upon completion of this educational activity, participants will be able to:

  • Describe the disease burden of OA, including the unmet need for effective pain management and impact of OA on disability and comorbidities
  • Apply current guideline recommendations to the management of OA and OA pain
  • Review clinical trial outcomes and current statuses of emerging therapies for OA and OA pain
  • Integrate communication strategies and patient-centered care considerations into routine clinical practice

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2021 through June 30, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.






Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Francis Berenbaum, MD, PhD
Consulting Fees: Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GlaxoSmithKline, Lilly, Merck Serono, Merck Sharp & Dohme, Nordic, Novartis, Peptinov, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, TRB Chemedica, UCB, 4Moving Biotech, 4P Pharma

Luana Colloca, MD, PhD, MS: TBD
Contracted Research: National Institutes of Health

David Hunter, MD
Consulting Fees: Taiwan Liposome Biopharmaceuticals, Kolon TissueGene

Jean Liew, MD, MS
Research grant: Pfizer

Mohammad Ursani, MD, FACP, FACR, RhMSUS has nothing to disclose

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Continue to Pretest